During the last session, Actinium Pharmaceuticals Inc (AMEX:ATNM)’s traded shares were 1.51 million, with the beta value of the company hitting -0.32. At the end of the trading day, the stock’s price was $1.89, reflecting an intraday gain of 1.07% or $0.02. The 52-week high for the ATNM share is $10.24, that puts it down -441.8 from that peak though still a striking 45.5% gain since the share price plummeted to a 52-week low of $1.03. The company’s market capitalization is $58.96M, and the average intraday trading volume over the past 10 days was 2.45 million shares, and the average trade volume was 552.44K shares over the past three months.
Actinium Pharmaceuticals Inc (ATNM) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ATNM has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.39.
Actinium Pharmaceuticals Inc (AMEX:ATNM) trade information
Actinium Pharmaceuticals Inc (ATNM) registered a 1.07% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.07% in intraday trading to $1.89, hitting a weekly high. The stock’s 5-day price performance is 34.04%, and it has moved by 70.27% in 30 days. Based on these gigs, the overall price performance for the year is -78.20%. The short interest in Actinium Pharmaceuticals Inc (AMEX:ATNM) is 2.21 million shares and it means that shorts have 14.51 day(s) to cover.
The consensus price target of analysts on Wall Street is $4.95, which implies an increase of 61.82% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4 and $24.26 respectively. As a result, ATNM is trading at a discount of -1183.6% off the target high and -111.64% off the low.
Actinium Pharmaceuticals Inc (ATNM) estimates and forecasts
In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 22.80%. While earnings are projected to return 34.00% in 2025, the next five years will return 11.77% per annum.
ATNM Dividends
Actinium Pharmaceuticals Inc is due to release its next quarterly earnings on 2024-Nov-13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Actinium Pharmaceuticals Inc (AMEX:ATNM)’s Major holders
Actinium Pharmaceuticals Inc insiders own 1.79% of total outstanding shares while institutional holders control 29.67%, with the float percentage being 30.21%. BLACKROCK INC. is the largest shareholder of the company, while 102.0 institutions own stock in it. As of 2024-06-30, the company held over 1.88 million shares (or 6.23% of all shares), a total value of $13.88 million in shares.
The next largest institutional holding, with 0.26 million shares, is of MARSHALL WACE, LLP’s that is approximately 0.8505% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.89 million.
Also, the Mutual Funds coming in first place with the largest holdings of Actinium Pharmaceuticals Inc (ATNM) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 938.63 shares. This amounts to just over 3.01 percent of the company’s overall shares, with a $1.77 million market value. The same data shows that the other fund manager holds slightly less at 822.18, or about 2.64% of the stock, which is worth about $1.55 million.
